Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibritumomab Tiuxetan Plus Rituximab in High Tumor Burden Indolent NHL
NCT00582166Phase 2Terminated
- Sponsor
- University of Wisconsin–Madison
- Start
- Jan 2005
- Primary completion
- Mar 2013
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibritumomab tiuxetan in non-Hodgkin lymphoma (NHL), sponsored by University of Wisconsin–Madison. Primary endpoint: Median Progression Free Survival at 9.5 months. Started Jan 2005; status: terminated.
02
Drugs
ibritumomab tiuxetan
03
Conditions
non-Hodgkin lymphoma (NHL)
Beyond the preview
Go deeper on NCT00582166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00582166.